Reassessing Reported Deaths and Estimated Infection Attack Rate during the First 6 Months of the COVID-19 Epidemic, Delhi, India.

COVID-19 India SARS-CoV-2 coronavirus disease epidemics infection attack rate infection fatality ratio mathematical modeling respiratory infections severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 26 2 2022
medline: 25 3 2022
entrez: 25 2 2022
Statut: ppublish

Résumé

India reported >10 million coronavirus disease (COVID-19) cases and 149,000 deaths in 2020. To reassess reported deaths and estimate incidence rates during the first 6 months of the epidemic, we used a severe acute respiratory syndrome coronavirus 2 transmission model fit to data from 3 serosurveys in Delhi and time-series documentation of reported deaths. We estimated 48.7% (95% credible interval 22.1%-76.8%) cumulative infection in the population through the end of September 2020. Using an age-adjusted overall infection fatality ratio based on age-specific estimates from mostly high-income countries, we estimated that just 15.0% (95% credible interval 9.3%-34.0%) of COVID-19 deaths had been reported, indicating either substantial underreporting or lower age-specific infection-fatality ratios in India than in high-income countries. Despite the estimated high attack rate, additional epidemic waves occurred in late 2020 and April-May 2021. Future dynamics will depend on the duration of natural and vaccine-induced immunity and their effectiveness against new variants.

Identifiants

pubmed: 35213800
doi: 10.3201/eid2804.210879
pmc: PMC8962916
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

759-766

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom

Références

Proc Biol Sci. 2007 Feb 22;274(1609):599-604
pubmed: 17476782
Lancet Glob Health. 2021 Feb;9(2):e110-e111
pubmed: 33197394
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Nature. 2020 Jul;583(7815):180
pubmed: 32636514
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Int J Infect Dis. 2020 Apr;93:284-286
pubmed: 32145466
Med Hypotheses. 2020 Nov;144:110209
pubmed: 33254516
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Lancet. 2020 Sep 5;396(10252):657
pubmed: 32891197
Science. 2020 Jul 24;369(6502):413-422
pubmed: 32532802
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017
pubmed: 32553130
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Science. 2020 Oct 30;370(6516):513
pubmed: 33122363
Clin Infect Dis. 2021 Dec 16;73(12):2344-2352
pubmed: 34117868
Clin Infect Dis. 2021 Aug 28;:
pubmed: 34453527
Lancet Infect Dis. 2021 Dec;21(12):1665-1676
pubmed: 34399090
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Trans R Soc Trop Med Hyg. 2022 Mar 2;116(3):242-251
pubmed: 34339514
J Infect Dis. 2021 Aug 23;:
pubmed: 34423821
Sci Transl Med. 2021 Jul 14;13(602):
pubmed: 34158411
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH